Ashurst advises on bid by Royalty Pharma for Elan Corporation
Ashurst advised J.P. Morgan and BofA Merrill Lynch as financial advisers to US investment firm Royalty Pharma on the cash offer for the entire issued and to be issued share capital of pharmaceutical group Elan Corporation plc.
The offer price is up to US$12 per Elan share including each Elan share represented by an Elan ADS, dependent on the outcome of a Dutch auction.